ICU Medical Inc. Common Stock (ICUI)
Stock · NASDAQ · Health Care
$163.15as of 10/16/2026
Price chart
Active signals
ICUI Signal Track Record
How signals performed across all stocks →What ICUI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | +0.0% | 52% | August 3, 2026 |
| Bollinger Band Breakdown | 23 | -2.4% | 26% | September 3, 2026 |
| Bollinger Band Breakout | 22 | +3.9% | 59% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +2.5% | 58% | June 22, 2026 |
| Any 20-session window (baseline) | -0.8% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardou…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 13,000
- Website
- www.icumed.com/
Fundamentals
- 1-day range
- $162.51$167.7
- Market cap
- $4.16B
- P/E (trailing)
- 139.19
- P/E (forward)
- 16.90
- EPS (trailing)
- $1.18
- Dividend yield
- —
- Beta
- 0.89
- Avg. volume
- 273.1K
How ICU Medical Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
ICU Medical Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ICUIICU Medical Inc. Common Stock$162.99▼ 2.54%Market cap $4.16BP/E 139.19$113.37$192.85
- IRTCiRhythm Holdings Inc. Common Stock$108.66▼ 0.63%Market cap $4.21BP/E —$100.7$212
- HAEHaemonetics Corporation Common Stock$118.28▼ 2.48%Market cap $3.86BP/E 56.08$48.17$121.19
- NVSTEnvista Holdings Corporation Common Stock$22.9▼ 2.55%Market cap $4.46BP/E 39.56$18.77$30.42
- MMEDMiniMed Group Inc. Common Stock$17.49▼ 2.83%Market cap $5.17BP/E —$10.65$24.43
- MMSIMerit Medical Systems Inc. Common Stock$89.2▼ 0.41%Market cap $5.24BP/E 36.22$59.74$94.75
- PLSEPulse Biosciences Inc Common Stock (DE)$44.43▼ 2.54%Market cap $2.65BP/E —$12.56$58.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ICUI ICU Medical Inc. Common Stock | $4.16B | 139.19 | $162.99 | ▼ 2.54% | $113.37$192.85 |
| IRTC iRhythm Holdings Inc. Common Stock | $4.21B | — | $108.66 | ▼ 0.63% | $100.7$212 |
| HAE Haemonetics Corporation Common Stock | $3.86B | 56.08 | $118.28 | ▼ 2.48% | $48.17$121.19 |
| NVST Envista Holdings Corporation Common Stock | $4.46B | 39.56 | $22.9 | ▼ 2.55% | $18.77$30.42 |
| MMED MiniMed Group Inc. Common Stock | $5.17B | — | $17.49 | ▼ 2.83% | $10.65$24.43 |
| MMSI Merit Medical Systems Inc. Common Stock | $5.24B | 36.22 | $89.2 | ▼ 0.41% | $59.74$94.75 |
| PLSE Pulse Biosciences Inc Common Stock (DE) | $2.65B | — | $44.43 | ▼ 2.54% | $12.56$58.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vascular Access Device Market by Type, Route of Insertion, Application, End User - Global Forecast to 2031Yahoo · 9/18/2026
- ICU Medical CFO Sells 6,381 Shares for $1.1 MillionYahoo · 9/17/2026
- ICU Medical CFO Brian Bonnell Sells 9,307 SharesYahoo · 9/17/2026
- ICU Medical, Inc. (ICUI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- Bonnell Brian Michael · August 31, 2026 · Sale1.1K @ $173.91
- Bonnell Brian Michael · August 31, 2026 · Sale4.6K @ $173.44
- Bonnell Brian Michael · August 31, 2026 · Sale1.9K @ $172.12
- Bonnell Brian Michael · August 31, 2026 · Sale1.7K @ $171.05
- Woolson Daniel · August 13, 2026 · Sale5.4K @ $181.33
- Sousa Ben · August 12, 2026 · Sale2.3K @ $178.32
- Voigtlander Christian B. · August 11, 2026 · Sale8.9K @ $182.93
- Elisha W. Finney · August 11, 2026 · Sale378 @ $182.48
- Woolson Daniel · May 22, 2026 · Sale2.1K @ $132.21
- Sanzone Virginia Ruth · May 14, 2026 · Sale2.4K @ $124.08
- Hernandez Laurie · May 13, 2026 · Grant1.5K
- Hernandez Laurie · May 13, 2026 · Option Exercise1.3K
- Greenberg David C. · May 13, 2026 · Grant1.5K
- Greenberg David C. · May 13, 2026 · Option Exercise1.3K
- Abbey Donald · May 13, 2026 · Grant1.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 22.92M
- Total value held
- $2.88B
- Institutional holders
- 268
- Unknown3.61M
- Unknown2.68M
- Unknown1.22M
- Unknown1.11M
- Unknown983.8K
- Unknown968.1K
- Unknown701.3K
- Unknown646.4K
- Unknown611.2K
- Unknown605.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ICU Medical Highlighted in Zacks Industry Outlook
ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.
ICU Medical Highlighted in Zacks Industry Outlook. ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.